Selected Abstracts

Phase I Clinical Trial Demonstrates Safety and Efficacy of Repeated Intrathecal Mesenchymal Stem Cell-Derived Neural Progenitors in Progressive Multiple Sclerosis

Violaine K. Harris, James Stark, MD, Tamara Vyshkina, Gloria Joo, Valentina Stefanova, and Saud A. Sadiq, MD Presented at the International Society for Stem Cell Research's (ISSCR) 2017 Annual Meeting, held June 14-17, 2017 in Boston, Massachusetts.

Bioactivity and Micro RNA Profile of Mesenchymal Stem Cell Neural Progenitor-Derived Extracellular Vesicles

Shayna Zanker, John Tuddenham, Tamara Vyshkina, Violaine K. Harris, and Saud A. Sadiq, MD Presented at the International Society for Stem Cell Research's (ISSCR) 2017 Annual Meeting, held June 14-17, 2017 in Boston, Massachusetts.

Increased methionine sulfoxide levels in the CSF of multiple sclerosis patients

Zerina Balic, Fozia Mir, and Saud A. Sadiq, MD Presented at the American Academy of Neurology (AAN) 2017 Annual Meeting, held April 22-28, 2017 in Boston, Massachusetts

Cerebrospinal Fluid Biomarkers Associated with the Reparative Effects of Intrathecal MSC-NP Treatment in Patients with Progressive Multiple Sclerosis

John Tuddenham, Violaine K. Harris, Tamara Vyshkina, and Saud A. Sadiq, MD Presented at the American Academy of Neurology (AAN) 2017 Annual Meeting, held April 22-28, 2017 in Boston, Massachusetts.

Comprehensive analysis of the intrathecal B-cell response in patients with multiple sclerosis

Antara Finney-Stable, Allison Liang, Jerry Lin, and Saud A. Sadiq, MD Presented at the American Academy of Neurology (AAN) 2017 Annual Meeting, held April 22-28, 2017 in Boston, Massachusetts.

CSF Biomarkers of Disease Progression in Patients with Multiple Sclerosis

Shayna D. Zanker, Violaine K. Harris, and Saud A. Sadiq, MD Presented at the American Academy of Neurology (AAN) 2017 Annual Meeting, held April 22-28, 2017 in Boston, Massachusetts.

Intrathecal delivery of primary progressive MS cerebrospinal fluid induces behavioral deficits and spinal cord pathology in mice

Jamie Wong, Nathan Kung, Marwan Alahiri, and Saud A. Sadiq, MD Presented at the American Academy of Neurology (AAN) 2017 Annual Meeting, held April 22-28, 2017 in Boston, Massachusetts

Phase I Clinical Trial Demonstrates Safety and Efficacy of Intrathecal Autologous Mesenchymal Stem Cell-Derived Neural Progenitors (MSC-NPs) for the Treatment of Progressive Multiple Sclerosis

Violaine Harris, James Stark, Gloria Joo, Tamara Vyshkina, and Saud A. Sadiq, MD Presented at the American Academy of Neurology (AAN) 2017 Annual Meeting, held April 22-28, 2017 in Boston, Massachusetts.

Intrathecal treatment using autologous mesenchymal stem cell neural progenitors (MSC-NP) may improve established disability in MS: results of a phase I open-label trial

Violaine Harris, PhD, Leslie Blackshear, Gloria Joo, Tamara Vyshkina, Valentina Stefanova, and Saud A. Sadiq, MD Presented at the International Society of Stem Cell Research (ISSCR) annual meeting, held June 22-25, 2016 in San Francisco, CA, USA

Reparative effects of intrathecal MSC-NP cells in patients with multiple sclerosis mediated by trophic and immunomodulatory factors

John Tuddenham, Violaine Harris, PhD, Tamara Vyshkina and Saud Sadiq, MD Presented at the International Society of Stem Cell Research (ISSCR) annual meeting, held June 22-25, 2016 in San Francisco, CA, USA

Pages

Tisch MS Research Center of New York

521 West 57th Street
4th Floor
New York, NY 10019
(646) 557-3900

Privacy Policy

 

Support Tisch MS

Support Tisch MS and our innovative research leading to treatments that improve the lives of patients.